Advancing Tomorrow’s Cancer Medicines: Jacob Van Naarden Talks with Ken Herrmann and Johannes Czernin About Corporate Approaches to New Therapeutics Development

By sjmartinez • January 24, 2025

Van Naarden JS, Herrmann K, Czernin J. Advancing Tomorrow's Cancer Medicines: Jacob Van Naarden Talks with Ken Herrmann and Johannes Czernin About Corporate Approaches to New Therapeutics Development. J Nucl Med. 2025 Jan 23:jnumed.124.269354. doi: 10.2967/jnumed.124.269354. Epub ahead of print. PMID: 39848767.

Tags: Cardiology/Epi, Publications

Evaluating associations of oxylipin metabolites and fatty acids with incident and prevalent type 2 diabetes in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)

Downie CG, Highland HM, Howard AG, Alotaibi M, Elfassy T, Cordero C, Below JE, Carnethon M, Cheng S, Daviglus M, Garcia-Bedoya O, Kaplan R, Khambaty[...]

Safety and Effectiveness of a Novel Laser-Based Intravascular Lithotripsy System for Coronary Calcium: FRACTURE Study

McEntegart M, Budrys P, Sharma S, Spratt JC, Nef H, Jefferson B, Verouden N, Corrigan FE 3rd, De Silva K, Chatterjee D, Price M, Webb[...]

Pulmonary Index of Microcirculatory Resistance: A Novel Hemodynamic Index for Invasively Assessing the Pulmonary Microvasculature

Parikh RV, Klomhaus A, Chen JY, Assi A, Bassam K, Channick R, Fearon WF, Aboulhosn J, Saggar R. Pulmonary Index of Microcirculatory Resistance: A Novel[...]